British Journal of Haematology

Article	Citations
Myeloma patients with COVID‐19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine	140
B‐cell lymphoma mimicking relapsing polychondritis	117
Lower anti‐spike levels in B‐cell‐depleted patients after convalescent plasma transfusion suggest the need for repeated doses	99
Cell erythroid maturation approach: a new paradigm in the road map towards a cure for β‐thalassaemia syndromes	85
Positron emission tomography derived metrics in relapsed or refractory large B‐cell lymphoma with residual disease before autologous stem cell transplant	81
Challenges and solutions to superior chimeric antigen receptor‐T design and deployment for B‐cell lymphomas	81
Clinicopathological characteristics and long‐term outcomes of plasmablastic lymphoma in British Columbia	75
Exome sequencing in high and low fetal haemoglobin Arab–Indian haplotype sickle cell disease	72
What complements complement in transplant‐associated thrombotic microangiopathy?	71
Safety and efficacy of a Hb‐triggered single‐unit red cell transfusion policy for haemato‐oncological inpatients	70
Long‐term outcomes of avascular necrosis in sickle cell disease using joint‐specific patient‐reported outcome measures: Results from a multicentre study	68
Burden of vaso‐occlusive crisis, its management and impact on quality of life of Indian sickle cell disease patients	65
Clinical perspectives on post‐induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation	65
Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network	61
Issue Information	56
Age, GVHD prophylaxis, and timing matter in thrombotic microangiopathy after haematopoietic cell transplantation—A secondary CIBMTR analysis	52
Asparagine transport through SLC1A5/ASCT2 and SLC38A5/SNAT5 is essential for BCP‐ALL cell survival and a potential therapeutic targ	52
Whole‐blood transcriptome analysis reveals distinct gene expression signatures in paediatric patients with sickle cell anaemia before and after exercise	50
MN1::ETV6‐positive de novo T‐cell acute lymphoblastic leukaemia is sensitive to venetoclax: A case report	50
Prevalence of kidney health genetic variants in adults with sickle cell nephropathy	49
Real‐world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study	49
Identification of new candidate drugs in myelodysplastic syndromes with splicing factor mutations by transcriptional profiling and connectivity map analysis	48
Difficult‐to‐treat primary immune thrombocytopenia in adults: Prevalence and burden. Results from the CARMEN‐France registry	48
Outcomes of daratumumab–bortezomib–thalidomide–dexamethasone in treatment‐naive systemic AL amyloidosis	46
Zanubrutinib for the treatment of Bing–Neel syndrome	45

Clinical and molecular characteristics of paediatric mature B‐cell acute lymphocytic leukaemia and non‐Hodgkin lymphoma with bone marrow involvement: A joint study between the CCCG leukaemia and lymph	45
Low levels of minimal residual disease after induction chemotherapy for BCR‐ABL1‐negative acute lymphoblastic leukaemia in adults are clinically relevant	44
The 12‐week kinetics of anti‐SARS‐CoV‐2 antibodies in different haematological cancers after vaccination with BNT162b2	44
Risk of recurrent venous thromboembolism in patients with autoimmune diseases: data from the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) registry	44
Pathogenesis, risk factors and therapeutic options for autoimmune haemolytic anaemia in the post‐transplant setting	43
Comprehensive analysis of relapsed‐refractory mature B‐cell non‐Hodgkin lymphoma in children and adolescents	42
A pilot study tracking immune cell subsets and activation profiles in adults with haemophagocytic lymphohistiocytosis treated with anakinra	42
A UK consensus algorithm for early treatment modification in newly diagnosed systemic light‐chain amyloidosis	41
Indirect presentation of mismatched human leukocyte antigen‐B associates with outcomes of cord blood transplantation	41
A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complet	40
Immune‐mediated thrombocytopenia and IL‐6‐mediated thrombocytosis observed in idiopathic multicentric Castleman disease	38
Van der WaltJ., OraziA., ArberD. A. (editors) Diagnostic Bone Marrow HaematopathologyCambridge, UK: Cambridge University Press, 2021. ISBN 978‐1‐107‐14 500‐9.	38
Adjunctive viral cell culture supports treatment decision‐making in patients with secondary humoral immunodeficiency and persistent SARS‐CoV‐2 infection	37
Issue Information	37
Graham Serjeant, Sickle Cell, Jamaica and Beyond: A Life, Ian Randle Publishers (Kingston and Miami), 2021	36
Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis	36
Lenalidomide in combination with R‐ESHAP in patients with relapsed or refractory diffuse large B‐cell lymphoma: A phase 2 study from GELTAMO	35
Issue Information	34
Bone marrow pseudo‐Gaucher cells demonstrating haemophagocytosis associated with extranodal NK/T cell lymphoma, nasal type	34
The impact of clonal diversity and mosaicism on haematopoietic function in Fanconi anaemia	34
A sinister case of pseudothrombocytosis	32
High risk of relapse with intermediate dose cytarabine for consolidation in young favourable‐risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis an	32
Management of luspatercept therapy in patients with transfusion‐dependent β‐thalassaemia	31
Childhood aggressive B‐cell non‐Hodgkin lymphoma in low–middle‐income countries	31
Rivaroxaban for the treatment of superficial vein thrombosis, experience at King’s College Hospital	31
Macrothrombocytopenia and stomatocytosis in sitosterolaemia	30
Haploidentical haematopoietic stem cell transplantation for TP53‐mutated acute myeloid leukaemia	29
In vivo 18F‐fluoride‐PET imaging reveals pronounced heterogeneity in bone formation in multiple myeloma patients	28
Accelerated death of megakaryocytes from Wiskott–Aldrich syndrome patients	28
Can circulating CD34+ cell count be used for the prognosis of myelofibrosis?	28
Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial	28
Issue Information	28
Diagnostic value of multigene sequencing for inherited thrombocytopenia	28
Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross‐sectional survey	27
Inherited cancer predisposing mutations in patients with therapy‐related myeloid neoplasms	27
Correctly marking the 70th anniversary of Castleman disease—Response	27
The significance of mixed chimaerism and cell lineage chimaerism monitoring in paediatric patients post haematopoietic stem cell transplant	27
Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia	26
The role of genetics in refractory immune thrombocytopenia	26
Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma	26
Retraction statement: First report of novel heterozygous WRAP53 p.Ala522Glyfs*8 mutation associated dyskeratosis congenita	25
Case series: CYP Inhibition and low dose ibrutinib for steroid‐refractory chronic graft‐versus‐host disease	25
Issue Information	25
	25
Finding the best haematopoietic stem cell transplant regimen for GATA2 haploinsufficiency: how close are we?	24
Hepatic haemophagocytosis in haematology patients with hepatic dysfunction: prognostic impact and contribution of liver biopsy combined with the haemophagocytic syndrome diagnostic score (HScore)	24
In situ follicular neoplasia with translocation of BCL6 – a new variant with different immunohistochemical properties	24
The impact of surveillance imaging after curative‐intent radiotherapy for limited‐stage follicular lymphoma	24
	24
Vaccine‐induced immune thrombocytopenia and thrombosis: The decline in anti‐platelet factor 4 antibodies is assay‐dependent	23

Mortality trends of chronic lymphocytic leukaemia in the United States with the emergence of targeted therapy	23
CAR‐T cell therapy is superior to standard of care as second‐line therapy for large B‐cell lymphoma: A systematic review and meta‐analysis	23
What does the term ‘sickle cell disease’ mean?	23
Oxygen gradient ektacytometry does not predict pain in children with sickle cell anaemia	23
How I manage myeloproliferative neoplasm‐unclassifiable: Practical approaches for 2022 and beyond	23
Issue Information	22
Impact of community health workers on quality of life in adolescents and young adults with sickle cell disease: The SHIP‐HU study	22
Novel identification of t(14;18)(q32;q21)/IGH::MALT1 in chronic lymphocytic leukaemia	22
Issue Information	22
Immunogenicity and clinical effectiveness of mRNA vaccine booster against SARS‐CoV‐2 Omicron in patients with haematological malignancies: A national prospective cohort study	22
COVID‐19 vaccine response in chronic lymphocytic leukaemia is more than just seroconversion	22
Prolonged platelet hyperactivity after COVID‐19 infection	22
R‐CHOP treatment for patients with advanced follicular lymphoma: Over 15‐year follow‐up of JCOG0203	21
Daratumumab for refractory immune‐mediated thrombotic thrombocytopenic purpura	21
Immune response and adverse events after vaccination against SARS‐CoV‐2 in adult patients with transfusion‐dependent thalassaemia	21
Clinico‐biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi‐centric observational study	21
Secondary primary malignancies after CD‐19 directed CAR‐T‐cell therapy in lymphomas: A report from the Italian CART‐SIE study	21
Increasing insight in the value of repetitive COVID‐19 vaccination in patients with haematological malignancies in the Omicron era	21
Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia	21
Issue Information	20
Immunothrombosis: a COVID‐19 concerto	20
	20
Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant	20
Comprehensive proteomic analysis reveals dynamic phospho‐profiling in human early erythropoiesis	20
Clinical significance of the immunoglobulin G heavy‐chain repertoire in peripheral blood mononuclear cells of adult T‐cell leukaemia–lymphoma patients receiving mogamulizumab	20
Accelerated low‐density neutrophil transition in sickle cell anaemia may contribute to disease pathophysiology	20
A novel ATRX variant with splicing consequences in myelodysplastic syndrome with acquired alpha thalassaemia	20
Spontaneous splenic rupture as initial presentation of diffuse large B‐cell lymphoma	20
Issue Information	19
Issue Information	19
Paediatric ambiguous lineage leukaemia with monocytic differentiation at diagnosis: case series and review of literature	19
The impact of COVID‐19 vaccination on patients with a history of heparin‐induced thrombocytopenia	19
Issue Information	19
Intra‐ and extracellular crystal deposition in a case of amyloid light chain amyloidosis	19
Novel RASGRP2 variants in platelet function defects: Indian study	19
The Frontiers of Plasma Cell Neoplasms JiFeng Yu and Peter Y. Z. Jiang (editors) Amazon.com direct publishing, USA, 2021 (ISBN: 9798589451924).	19
Radiological evidence of resolution of fatty marrow after bone marrow transplantation	18
Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy	18
Allogeneic haematopoietic stem cell transplantation for adult T‐lymphoblastic lymphoma: A real‐world multicentre analysis in China	18
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment‐free remission period after imatinib discontinuation: Results of the French Nilo post‐STIM	18
A British view on the management of Waldenström macroglobulinemia	18
Rare and fatal complication of immune checkpoint inhibition: a case report of haemophagocytic lymphohistiocytosis with severe lichenoid dermatitis	18
Immunophenotypic clustering in paediatric acute myeloid leukaemia	18
Differentiation therapy using low‐dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16‐RARA	18
Cup‐shaped nuclei in acute promyelocytic leukaemia	18
A 4‐gene prognostic index for enhancing acute myeloid leukaemia survival prediction	18
Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression	17
COSMIC, chemotherapy plus ofatumumab at standard or mega‐dose in chronic lymphocytic leukaemia, a phase II randomised study	17
Issue Information	17
Comparative study of therapy‐related and de novo adult b‐cell acute lymphoblastic leukaemia	17
Puumala virus‐induced lymphocyte anomalies	17
Alternative donor transplantation for severe aplastic anaemia in 2021: haplo donor, cord blood or both?	17
β‐Thalassemia in childhood: Current state of health in a high‐income country	17
SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T‐cell neoplasms	17
Hydroxyurea therapy decreases coagulation and endothelial activation in sickle cell disease: a Longitudinal Study	17
A novel MYC–non‐IG fusion in refractory diffuse large B‐cell lymphoma	17
Giant pelvic haemophilic pseudotumor	17
Posters	16
Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP‐CML) exist? That is the question.	16
Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L‐ASP: A retrospective analysis with an ASP‐based protocol in adult patients with acute lympho	16
Autologous stem cell transplantation in the age of ANDROMEDA	16
Evidence creation for myelofibrosis: Challenges and opportunities	16
Parameters of long‐term response with CD28‐based CD19 chimaeric antigen receptor‐modified T cells in children and young adults with B‐acute lymphoblastic leukaemia	16
The (near) miracle of therapy in chronic myeloid leukaemia	16
Accessory spleens recapitulate the immune microenvironment of the main spleen in immune thrombocytopenia	16
A Case of Postural‐Induced Peri‐Orbital Petechiae	16
Transfusion Medicine: Case studies and Clinical Management, Second EditionBy AleksandarMijovic, Springer Nature Switzerland. 2023. pp. 1–155. ISBN: 978‐3‐031‐31461‐2	16
Issue Information	16
Clinical outcomes and immune responses to SARS‐CoV‐2 vaccination in severe aplastic anaemia	16
Needs assessment in adults and parents of children living with sickle cell disease in Jamaica	16
Applying current smouldering myeloma risk models to a UK single‐centre cohort and clinical features at progression	16
Delayed haemolytic transfusion reaction in paediatric patients with sickle cell disease: A retrospective study in a French national reference centre	16
A single‐institution pre–post comparison of subcutaneous immunoglobulin replacement therapy in allogeneic haematopoietic cell transplantation recipients	16
Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R‐MIV) in patients with primary CNS lymphoma including recent	16
Leukaemic blasts in a urine specimen in acute myeloid leukaemia with CEBPA mutation	15
Functional impairment of erythropoiesis in Congenital Dyserythropoietic Anaemia type I arises at the progenitor level	15
A novel gain‐of‐function PIP4K2A mutation elevates the expression of β‐globin and aggravates the severity of α‐thalassemia	15
Clinical utility of investigations in triple‐negative thrombocytosis: A real‐world, multicentre evaluation of UK practice	15
Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma	15
VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome‐negative B‐precursor acute lymphoblastic leukaemia in first relapse	15

	15
AML in the elderly—A global view	15
Favourable outcomes of double‐hit/double‐expressor lymphoma and high‐grade B‐cell lymphoma, not otherwise specified after early dose‐intensive treatment and up‐front autologous stem cell transplantati	15
Rounding off our Global View series	15
Integrative epigenomics in chronic lymphocytic leukaemia: Biological insights and clinical applications	15
COVID‐19 infection in primary central nervous system lymphoma treatment: Who is most at risk?	15
Low incidence of hyperacute graft‐versus‐host disease (GVHD) with effective GVHD prophylaxis based on anti‐thymocyte globulin	15
In vitro assessment of the sensitivity to APR‐246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients	15
Machine/deep learning‐assisted hemoglobin level prediction using palpebral conjunctival images	15
CXCR4 antagonists disrupt leukaemia‐meningeal cell adhesion and attenuate chemoresistance	15
BCR::ABL1 transcripts and clinical outcome ‐ interrogating the technique	14
	14
Whole‐blood CCR7 expression and chemoattraction in red blood cell alloimmunization	14
	14
In vitro anti‐lymphoma activity of the first‐in‐class pan‐NOTCH transcription inhibitor CB‐103	14
Higher than normal mitochondrial DNA content associated with better outcome in acute promyelocytic leukaemia? Maybe	14
Don't forget cord blood in non‐remission acute myeloid leukaemia!	14
Digging into the HLA pockets: A new association with acute leukaemias	14
A real‐world study of immune thrombocytopenia management during the COVID‐19 pandemic in the UK	14
Phase Ib study of eltrombopag and azacitidine in patients with high‐risk myelodysplastic syndromes and related disorders (the ELASTIC study)	14
False‐positive heparin‐PF4 latex immunoturbidimetric assay due to lupus anti‐coagulant interference: a case report	14
Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data	14
Ras‐associated autoimmune lymphoproliferative disorder	14
Clinical features of primary vitreoretinal lymphoma developing extra‐central nervous system (CNS)/testicular lymphomas with or without CNS involvement: A single‐centre study of 1	14
Auer rod‐like inclusions in cerebrospinal fluid in accelerated phase chronic lymphocytic leukaemia	14
Liquid biopsy in Hodgkin lymphoma – moving beyond the proof of principle	14
Issue Information	14
IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1+ and BCR::ABL1‐like B‐acute lymphoblastic leukaemia	14
Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients	14
Non‐pharmacological supportive‐care interventions in acute myeloid leukaemia: a review of randomised controlled trials	14
Persistent albuminuria and chronic kidney disease in adults with sickle cell anaemia: Results from a multicenter natural history study	14
Reduction in seroprevalence of viral transfusion‐transmitted infections in southwest Nigeria in children with sickle cell disease using an enhanced screening strategy	14
Rolling the DICEP on lymphoma salvage treatments? Choose wisely	14
Using the in vitro drug sensitivity test to identify candidate treatments for transient abnormal myelopoiesis	13
Sequential loss of B‐cell target antigens in multiply relapsed high‐grade B‐cell lymphoma treated with targeted therapies	13
New findings and new methods on macrophages in primary immune thrombocytopenia	13
T cell immune profiling of respiratory syncytial virus for the development of a targeted immunotherapy	13
Dose reductions in immunoglobulin replacement are associated with increased antibiotic usage in patients with antibody deficiency	13
Erythrophagocytosis in a patient with myelodysplastic syndrome with excess blasts‐1 with isolated del(6q)	13
ATM serine/threonine kinase germline mutations in chronic lymphocytic leukaemia come in different flavours	13
Computational analysis of a microRNA signature for poor prognosis suggests a microRNA‐controlled stemness pathway in paediatric acute leukaemia	13
Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics‐guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with si	13
MYC‐induced cytidine metabolism regulates survival and drug resistance via cGas‐STING pathway in mantle cell lymphoma	13
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti‐leukaemic potential and alloreactivity across major human leukoc	13
Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti‐CD38 therapy	13
Quality of life in childhood immune thrombocytopenia: Revision of the Kids' ITP Tools (KIT)	13
Caplacizumab: A game changer also in pregnancy‐associated immune‐mediated thrombotic thrombocytopenic purpura?	13
POU6F2, a novel fusion partner of NUP98 in acute myeloid leukaemia: A case report	13
Cause of death and excess mortality in patients with lower‐risk myelodysplastic syndromes (MDS): A report from the European MDS registry	13
	13
Therapeutic plasma exchange in severe refractory autoimmune heparin‐induced thrombocytopenia with thrombosis	13
Humoral and cellular responses to SARS‐CoV‐2 in patients with B‐cell haematological malignancies improve with successive vaccination	13
Gynaecological and reproductive health of women with telomere biology disorders	13
Identification and management of preoperative anaemia in adults: A British Society for Haematology Guideline update	13
Cost‐effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola‐R‐CHP) in previously untreated diffuse large B‐cell lymphoma in Germany	13
Orals	13
Refractory immune thrombocytopenia in adults: Towards a new definition	13
Common‐sense combination therapy in refractory immune thrombocytopaenia	13
Issue Information	13
Recurrent mutations in multiple components of the SWI/SNF complex in myelodysplastic syndromes and acute myeloid leukaemia	13
Lenalidomide maintenance following high‐dose therapy and autologous haematopoietic stem cell transplantation in chemo‐resistant or high‐risk non‐Hodgkin lymphoma: A phase I/II st	13
Acute promyelocytic leukaemia associated with atypical basophilia	13
Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single‐arm FIL‐BRB trial	13
Would you like to take some more ruxolitinib after your fedratinib?	13
Clover leaf nuclear morphology in chronic lymphocytic leukaemia with typical immunophenotype and absence of trisomy 12	12
Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double‐blind, placebo‐controlled phase 3 studies and their open‐label extension	12
Identification of the minimum requirements for successful haematopoietic stem cell transplantation	12
Biomarkers of clinical severity in treated and untreated sickle cell disease: a comparison by genotypes of a single center cohort and African Americans in the NHANES study	12
Severe neonatal haemolytic anaemia caused by compound heterozygous KLF1 mutations: report of four families and literature review	12
Dual antiviral therapy in haematological patients with protracted SARS‐CoV‐2 infection	12
Whole‐exome sequencing uncovered genetic diagnosis of severe inherited haemolytic anaemia: Correlation with clinical phenotypes	12
Inequalities in geographic barriers and patient representation in lymphoma clinical trials across England	12
Humanized anti‐CD25 monoclonal antibody replaces methotrexate as acute graft‐versus‐host disease prophylaxis in haploidentical allogeneic haematopoietic stem cell transplantation	12
Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma	12
Leukaemic transformation in a 10‐year‐old girl with SRP54 congenital neutropenia	12
HTLV‐1 and blood donation	12
Promoter‐centred chromatin interactions associated with EVI1 expression in EVI1+3q− myeloid leukaemia cells	12
Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score‐matched cohort study	12
Haematopoietic stem cell transplantation for hepatitis‐associated aplastic anaemia and non‐hepatitis‐associated aplastic anaemia: A propensity score‐matched analysis	12
A successful clinical trial ecosystem offers equal opportunities for all citizens	12
Hydroxy‐wybutosine tRNA modifications as indicators of disease progression and therapeutic targets in leukaemia	12
Therapy for isocitrate dehydrogenase 2 (IDH2)R172‐mutant acute myeloid leukaemia	12
COVID‐19 in patients with paroxysmal nocturnal haemoglobinuria: an Italian multicentre survey	12
Guideline development for prevention of transfusion‐associated graft‐versus‐host disease: reduction of indications for irradiated blood components after prestorage leukodepletion of blood compo	12
Induction of robust humoral immunity against SARS‐CoV‐2 after vaccine administration in previously infected haematological cancer patients	12
Myelodysplastic syndrome associated‐haemophagocytic lymphohistiocytosis: A retrospective study of 15 cases in a single centre	12
Qualitative study to support the content validity of the immune thrombocytopenia (ITP) Life Quality Index (ILQI)	12
Distinct karyotypic and mutational landscape in trisomy AML	12
Feasibility for non‐invasive prenatal fetal blood group and platelet genotyping by massively parallel sequencing: A single test system for multiple atypical red cell, platelet and quality control mark	12
Impact of hydroxycarbamide treatment on the whole‐blood transcriptome in sickle cell disease	12
Concomitant HIV‐associated plasmablastic lymphoma and visceral leishmaniasis at initial presentation	12
Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation	11
Quality of life in advanced‐stage, asymptomatic, non‐bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful‐waiting	11
Outcomes and prognostic factors associated with relapse after haploidentical stem cell transplantation for paediatric T‐cell acute lymphoblastic leukaemia	11
Issue Information	11